Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Karuna Therapeutics, Inc. is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer’s Disease. The study aims to assess the safety and efficacy of KarXT in adults with mild to severe Alzheimer’s Disease experiencing moderate to severe psychosis. This research is significant as it addresses a critical need for effective treatments in this patient population.
The intervention being tested is KarXT, a drug designed to treat psychosis associated with Alzheimer’s Disease. It is compared against a placebo to determine its effectiveness and safety.
The study is interventional with a randomized, parallel assignment. It employs a quadruple masking approach, meaning the participant, care provider, investigator, and outcomes assessor are unaware of the treatment allocation. The primary purpose is treatment-focused.
The study began on September 26, 2024, with the primary completion date yet to be announced. The last update was submitted on July 22, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This update from Karuna Therapeutics could positively impact the company’s stock performance and investor sentiment, especially if the results demonstrate significant efficacy and safety. In the competitive landscape of Alzheimer’s treatments, successful outcomes could position KarXT as a valuable asset.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.